Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
RANCHO CUCAMONGA, CA / / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits BAQSIMI®, including its potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill PetersChief Financial Officer(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
S&P 500 Gains & Losses Today: J.M. Smucker Stock Sinks, Tesla Shares Recover
The S&P 500 added 0.6% on Tuesday, June 10, 2025, as investors awaited developments in trade negotiations between the U.S. and China. Tesla shares moved higher as social media posts from CEO Elon Musk promoted the company's upcoming robotaxi launch. Declining sales of sweet baked goods weighed on the performance J.M. Smucker, and shares of the food maker U.S. equities indexes climbed Tuesday as trade representatives from the U.S. and China engaged in talks for a second straight day. Both the S&P 500 and the Nasdaq ended the session with gains of around 0.6%, while the Dow was up 0.3%. Read Investopedia's full coverage of the day's trading here. Intel (INTC) shares surged nearly 8%, gaining the most of any stock in the S&P 500. Shares of other semiconductor makers also moved higher as the U.S.-China talks bolstered hopes for looser export restrictions. Although Apple (AAPL) said it will end support next year for Mac computers built with Intel's processors, providing more evidence of the transitional period faced by the chipmaker, analysts have expressed confidence in the ability of CEO Lip-Bu Tan, who took the reins of in March, to drive a turnaround at Intel. Caesars Entertainment (CZR) shares jumped 5.7%. TD Cowen analysts reiterated a "buy" rating on the casino operator's stock, noting that the company's loyalty program has helped drive entertainment, food and beverage, and lodging revenues to supplement its traditional earnings from gaming operations. The analysts also pointed to potential growth in its digital business. Tesla (TSLA) stock also added 5.7% as social-media posts from CEO Elon Musk hinted at the impending launch of the company's autonomous ride hailing service in Austin, Texas. Tuesday's move higher extended a recovery for the stock that kicked into gear during the previous session as tensions appeared to ease between Musk and President Donald Trump. Warner Bros. Discovery (WBD) shares advanced 5%, a day after the media conglomerate announced plans to split into two companies. One entity will house Warner's TV and movie studios along with the HBO Max streaming service, while the other will be home to its cable channels and the Discovery+ streaming service. The stock initially surged following the Monday-morning announcement, gave back those gains to end Monday's session lower, and then rose again today. Food maker J.M. Smucker (SJM) reported lower-than-expected sales for its fiscal fourth quarter of 2025, and its profit guidance for fiscal 2026 also came in below expectations. The maker of Folgers coffee and Uncrustables handheld sandwiches said that volume/mix impacts contributed to a year-over-year decline in net sales, especially declines in dog treats and sweet baked goods. Smucker shares sank nearly 16%, losing the most of any S&P 500 stock on Tuesday. Universal Health Services (UHS) fell 2.9% on Tuesday, extending losses posted in the prior session after the hospital operator's chief financial officer discussed a decline in the volume of surgical procedures at its facilities. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Los Angeles Times
an hour ago
- Los Angeles Times
US stocks drift closer to their record as Wall Street waits to see what US-China talks will bear
NEW YORK — U.S. stocks drifted closer to their all-time high on Tuesday as the wait continued to hear what will come of trade talks between the United States and China. The S&P 500 rose 0.5% as talks between the world's two largest economies carried into a second day. The Dow Jones Industrial Average added 105 points, or 0.2%, and the Nasdaq composite gained 0.6%. Stocks have roared higher since dropping roughly 20% below their record two months ago, when President Donald Trump shocked financial markets with his announcement of tariffs that were so stiff that they raised worries about a possible recession. Much of the rally has been due to hopes that Trump would lower his tariffs after reaching trade deals with countries around the world, and the S&P 500 is back within 1.7% of its record set in February. It's getting to be time to see whether such hopes were warranted. The talks with China were going 'really, really well,' U.S. Secretary of Commerce Howard Lutnick said Tuesday evening in London, where the talks were being held. The two sides worked on 'all sorts of trade issues,' he said, according to a video clip posted by the Chinese state broadcaster CGTN. Both the United States and China have put many of their tariffs announced against each other on pause as talks continue. Even though many tariffs are on hold for the moment, they're still affecting companies and their ability to make profits because of all the uncertainty they've created. Designer Brands, the company behind the DSW shoe store chain, became the latest U.S. company to yank its financial forecasts for 2025 because of 'uncertainty stemming primarily from global trade policies.' The company, which also owns the Keds, Jessica Simpson and other shoe brands, reported a larger loss for the start of the year than analysts were expecting, and its revenue also fell short of forecasts. CEO Doug Howe pointed to 'persistent instability and pressure on consumer discretionary' spending, and the company's stock tumbled 18.2%. The uncertainty is moving in both directions, to be sure. A survey released Tuesday of optimism among small U.S. businesses improved a bit in May. 'While the economy will continue to stumble along until the major sources of uncertainty are resolved, owners reported more positive expectations on business conditions and sales growth,' according to Bill Dunkelberg, chief economist at the National Federation of Independent Business. On Wall Street, J.M. Smucker fell 15.6% even though its results for the latest quarter topped analysts' expectations. Its revenue fell short of expectations, as did its forecast for profit in the upcoming year. Tesla helped to make up for such losses after rising 5.7%. The electric vehicle company has been recovering since tumbling last week as Elon Musk's relationship with Trump imploded. That raised fear about possible retaliation by the U.S. government against Tesla. Shares that trade in the United States of chipmaking giant Taiwan Semiconductor Manufacturing Co. rose 2.6% after the company known as TSMC said its revenue in May jumped nearly 40% from the year earlier. Casey's General Stores leaped 11.6% after the chain of convenience stores based in Ankeny, Iowa, reported a stronger profit for the latest quarter than analysts expected. It credited strength in sales of hot sandwiches and other items. All told, the S&P 500 rose 32.93 points to 6,038.81. The Dow Jones Industrial Average added 105.11 to 42,866.87, and the Nasdaq composite climbed 123.75 to 19,714.99. In stock markets abroad, indexes were mixed amid mostly modest movements across Europe and Asia. A 0.8% drop for Germany's DAX and a 0.6% gain for South Korea's Kospi were two of the bigger moves. In the bond market, the yield on the 10-year Treasury eased to 4.47% from 4.49% late Monday. Choe writes for the Associated Press.
Yahoo
an hour ago
- Yahoo
Opinion - Trump shouldn't import socialist price controls
Remember when Republican presidential candidate Donald Trump castigated 'Comrade Kamala' Harris, then the Democratic nominee, for supporting price controls? It wasn't that long ago — just last August. At a campaign rally in Pennsylvania, Trump told the crowd: 'In her speech yesterday, Kamala went full Communist … She wants to destroy our country. After causing catastrophic inflation, Comrade Kamala announced that she wants to institute socialist price controls.' Harris's price controls were largely aimed at food in grocery stores, though she also frequently touted the 2022 Inflation Reduction Act's backdoor price controls — under the guise of 'negotiations' — on a certain number of expensive drugs. Trump was right to criticize Harris for supporting price controls on food, as well as prescription drugs. And, given the election results, it seems the public agreed with him. Price controls are the progressive left's go-to solution for almost all economic problems. But price controls virtually always lead to unintended consequences: shortages of the price-controlled products or services; lower quality as manufacturers cut corners to meet government-imposed price points; less innovation, since companies don't know if they'll be allowed to recover their costs; and a black market where people pay more to get what they want or need. So it's puzzling to see Trump now proposing a version of drug price controls himself. It's not the first time, either. During his first term, Trump pushed for 'drug importation,' encouraging U.S. citizens to buy medicines from countries like Canada — even though the FDA has warned those drugs could be fake or substandard. The effort fizzled, and even Florida, which tried a state-level importation scheme, eventually abandoned its program. Trump's latest idea is called 'Most Favored Nation' pricing. Details are thin, but a recent executive order says, 'To the extent consistent with law, the Secretary of Health and Human Services (Secretary) shall facilitate direct-to-consumer purchasing programs for pharmaceutical manufacturers that sell their products to American patients at the most-favored-nation price.' That 'most-favored' country will almost certainly be one with government-run health care — that is, socialized medicine. These systems are known for price controls, which lead to shortages, long wait times, and limited access to cutting-edge treatments. The goal of Most Favored Nation is to lower prices on expensive drugs. Americans do pay more for brand-name drugs than patients elsewhere. But they also pay less for generics, which account for roughly 90 percent of all prescriptions. One reason for the disparity is the middlemen in our system, known as pharmacy benefit managers. Their job is to negotiate lower prices with drugmakers. But those savings often don't make it to patients. Instead, pharmacy benefit managers keep a big chunk for themselves — on average, $0.42 of every $1 spent on brand-name drugs in the commercial market, by one estimate. In many cases, those pharmacy benefit manager cuts are larger than the total price of the drug in Europe. It's clear our system could work better. 'Shark Tank' entrepreneur Mark Cuban launched the Cost Plus Drug Company in 2022 to bypass these middlemen. The Cost Plus website says, 'Our prices are the true cost to get each medication from the manufacturer to you. We cut out the pharmacy middlemen and negotiate directly with manufacturers to get the best possible price.' The company tacks on 15 percent for overhead and a $5 filling fee. While customers may not save much on some widely used generics, the discounted prices on more expensive brand name and generic drugs are significantly lower than what most people would experience at their local pharmacy. Cost Plus has hundreds of drugs for nearly 100 listed medical conditions, and it's looking to add new drugs all the time. It's only been in business a few years and is working to expand. We also shouldn't ignore the fact that Americans are subsidizing below-market prices abroad. The United States funds a disproportionate share of global pharmaceutical innovation, while other wealthy nations impose price caps and benefit from our investment. If Trump wants to stop other countries from taking advantage of us, he should take the approach he's using to get countries to pay more for defense. Cuban's Cost Plus experiment proves we don't need Most Favored Nation pricing. Let socialized systems keep their socialized prices, limited access and denial of care. Tweaking a line Trump likes to use and applying it to prescription drugs: We don't need a new law. We just don't need a middleman. Merrill Matthews is a public policy and political analyst and the co-author of 'On the Edge: America Faces the Entitlements Cliff.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
